Furthermore, objective benefit from PD-1/PD-L1 blockade therapy is shown in only a fraction of patients of NSCLC, indicating that development of strategies to effectively predict and optimize the treatment response of primary resistant tumors lacking PD-L1 expression and immune infiltration is needed urgently. This evidence concerns the gene CD274 and non-small cell lung carcinoma.